KL 002
Alternative Names: KL-002Latest Information Update: 18 Sep 2023
At a glance
- Originator Kanglin Biotech
- Class Antiparkinsonians; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 06 Jun 2023 Preclinical trials in Parkinson's disease in China (Intracerebral) (Kanglin Biotech pipeline, June 2023)
- 01 Jun 2023 Kanglin Biotech plans a phase I trial for Parkinson's Dissease in China (Intracerebral) (NCT05882487)